Human Papilloma Virus (HPV) E7 Protein - Pipeline Review, H1 2016

  • ID: 3788921
  • Drug Pipelines
  • 104 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Advaxis, Inc.
  • Etubics Corporation
  • Genexine, Inc.
  • iBio, Inc.
  • Kite Pharma, Inc.
  • Selecta Biosciences, Inc.
  • MORE
Human Papilloma Virus (HPV) E7 Protein - Pipeline Review, H1 2016

Summary

‘Human Papilloma Virus (HPV) E7 Protein - Pipeline Review, H1 2016’, provides in depth analysis on Human Papilloma Virus (HPV) E7 Protein targeted pipeline therapeutics.

The report provides comprehensive information on the Human Papilloma Virus (HPV) E7 Protein, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Human Papilloma Virus (HPV) E7 Protein targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Human Papilloma Virus (HPV) E7 Protein
- The report reviews Human Papilloma Virus (HPV) E7 Protein targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Human Papilloma Virus (HPV) E7 Protein targeted therapeutics and enlists all their major and minor projects
- The report assesses Human Papilloma Virus (HPV) E7 Protein targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Human Papilloma Virus (HPV) E7 Protein targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Human Papilloma Virus (HPV) E7 Protein
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Human Papilloma Virus (HPV) E7 Protein development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Advaxis, Inc.
  • Etubics Corporation
  • Genexine, Inc.
  • iBio, Inc.
  • Kite Pharma, Inc.
  • Selecta Biosciences, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Human Papilloma Virus (HPV) E7 Protein Overview

Therapeutics Development

Human Papilloma Virus (HPV) E7 Protein - Products under Development by Stage of Development

Human Papilloma Virus (HPV) E7 Protein - Products under Development by Therapy Area

Human Papilloma Virus (HPV) E7 Protein - Products under Development by Indication

Human Papilloma Virus (HPV) E7 Protein - Pipeline Products Glance

Late Stage Products

Early Stage Products

Human Papilloma Virus (HPV) E7 Protein - Products under Development by Companies

Human Papilloma Virus (HPV) E7 Protein - Products under Development by Universities/Institutes

Human Papilloma Virus (HPV) E7 Protein - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Route of Administration

Assessment by Molecule Type

Human Papilloma Virus (HPV) E7 Protein - Companies Involved in Therapeutics Development

Advaxis, Inc.

AnGes MG, Inc.

Cancer Research Technology Limited

Etubics Corporation

Formune S.L.

Genexine, Inc.

Genticel S.A.

iBio, Inc.

Immunovaccine, Inc.

Inovio Pharmaceuticals, Inc.

Kite Pharma, Inc.

MedImmune, LLC

Selecta Biosciences, Inc.

Tomegavax, Inc.

Transgene SA

VLPbio

Human Papilloma Virus (HPV) E7 Protein - Drug Profiles

Antibodies to Target E7 for HPV Associated Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aptamer to Target HPV E7 Protein for Cervical Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

axalimogene filolisbac - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLSILSB-710c - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CerviVax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DPXE-7 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EDA-HPVE7 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETBX-041 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GLBL-101c - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GTL-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GTL-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GX-188E - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus [Serotype 16] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-3106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-3112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PVX-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SEL-701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TA-CIN - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-4001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Cervical Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target HPV E7 Protein for Cervical Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VGX-3100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vvax-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Human Papilloma Virus (HPV) E7 Protein - Dormant Projects

Human Papilloma Virus (HPV) E7 Protein - Discontinued Products

Human Papilloma Virus (HPV) E7 Protein - Featured News & Press Releases

Jun 15, 2016: Genticel to Present Clinical Results of GTL001 at EUROGIN 2016 Congress in Salzburg, Austria

Jun 15, 2016: Genticel to Present Preclinical Results of GTL002 at EUROGIN 2016 Congress in Salzburg, Austria

Jun 13, 2016: Genticel Announces Completion of Two Major Milestones in Preparation for Phase 3 Program of GTL001

Jun 08, 2016: Advaxis Announces First Patient Dosed in Phase 2 Trial Evaluating AXAL in Anal Cancer

Jun 06, 2016: Advaxis Announces Updated Data at ASCO from a Phase 2 Study of AXAL in Advanced Cervical Cancer Showing Promising Survival Rates Consistent with Earlier Reports

Jun 01, 2016: Genticel Announces Publication in ‘Clinical Cancer Research’ of Phase 1 Trial Results Supporting Safety, Tolerability and Immunogenicity of GTL001

Apr 25, 2016: Phase II Cervical Cancer Study with Advaxis’ Axalimogene Filolisbac Selected for Poster Discussion Session at the 2016 ASCO Annual Meeting

Apr 20, 2016: Genticel Reports Additional Results at 12 Months From Phase 2 Trial of HPV Immunotherapeutic Candidate, GTL001

Apr 20, 2016: New Preclinical Study Shows Immunovaccine’s DepoVax-based Cancer Vaccine May Improve Efficacy of Checkpoint Inhibitors

Apr 18, 2016: Late Breaking Data at AACR Annual Meeting from Advaxis Phase 2 Study of AXAL Highlights Potential of the Company’s Lm Technology™ Platform

Mar 30, 2016: Inovio Pharmaceuticals HPV Immunotherapy Selected as “Best Therapeutic Vaccine” by World Vaccine Congress

Mar 29, 2016: Advaxis Combination Trial with MedImmune Completes First Dose-Escalation Cohort

Mar 29, 2016: Inovio Updates INO-3112 HPV Immunotherapy Development Plan

Mar 23, 2016: Advaxis Hosts Research Reception to Review Late-Breaking AACR Abstract

Mar 07, 2016: Dosing Begins in High Dose Expansion Cohort in Phase 2 Study of Axalimogene Filolisbac in Patients With Recurrent Cervical Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 104List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Advaxis, Inc., H1 2016

Pipeline by AnGes MG, Inc., H1 2016

Pipeline by Cancer Research Technology Limited, H1 2016

Pipeline by Etubics Corporation, H1 2016

Pipeline by Formune S.L., H1 2016

Pipeline by Genexine, Inc., H1 2016

Pipeline by Genticel S.A., H1 2016

Pipeline by iBio, Inc., H1 2016

Pipeline by Immunovaccine, Inc., H1 2016

Pipeline by Inovio Pharmaceuticals, Inc., H1 2016

Pipeline by Kite Pharma, Inc., H1 2016

Pipeline by MedImmune, LLC, H1 2016

Pipeline by Selecta Biosciences, Inc., H1 2016

Pipeline by Tomegavax, Inc., H1 2016

Pipeline by Transgene SA, H1 2016

Pipeline by VLPbio, H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Discontinued Products, H1 2016 90List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Advaxis, Inc.
  • Etubics Corporation
  • Genexine, Inc.
  • iBio, Inc.
  • Kite Pharma, Inc.
  • Selecta Biosciences, Inc.
  • MORE
Human Papilloma Virus (HPV) E7 Protein Human Papilloma Virus (HPV) E7 protein belongs to a group of proteins called oncoproteins. It plays a role in viral genome replication by driving entry of quiescent cells into the cell cycle. E7 protein has both transforming and trans-activating activities. It induces the disassembly of the E2F1 transcription factor from RB1, with subsequent transcriptional activation of E2F1-regulated S-phase genes. Ii interferes with host histone deacetylation mediated by HDAC1 and HDAC2, leading to transcription activation. It plays an important role in the inhibition of both antiviral and antiproliferative functions of host inteferon alpha.

Human Papilloma Virus (HPV) E7 Protein pipeline Target constitutes close to 25 molecules. Out of which approximately 21 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase II, Phase I and Preclinical stages are 8, 2 and 11 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Our latest report Human Papilloma Virus E7 Protein – Pipeline Review, H1 2016, outlays comprehensive information on the Human Papilloma Virus (HPV) E7 Protein targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Human Papilloma Virus (HPV) E7 Protein targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Advaxis, Inc.
AnGes MG, Inc.
Cancer Research Technology Limited
Etubics Corporation
Formune S.L.
Genexine, Inc.
Genticel S.A.
iBio, Inc.
Immunovaccine, Inc.
Inovio Pharmaceuticals, Inc.
Kite Pharma, Inc.
MedImmune, LLC
Selecta Biosciences, Inc.
Tomegavax, Inc.
Transgene SA
VLPbio
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll